Ipsen announces it is no longer eligible for the PEA-PME scheme
Ipsen announces it is no longer eligible for the PEA-PME scheme
Ipsen (Euronext: IPN; ADR: IPSEY) announces that the Group is no longer eligible for the PEA-PME scheme (a French equity savings vehicle for small and mid-sized business enterprises) as of January 1st, 2018, in accordance with Articles L221-32-2 and D221-113-5 of the French Monetary and Financial Code.
As of January 1st, 2018, the Group will no longer comply with the thresholds set by the legislator for eligibility to the PEA-PME scheme, determined on the basis of two fiscal years preceding the acquisition date of the securities i.e. the consolidated financial statements for 2016, in accordance with the French regulations.
Consequently, Ipsen Group’s securities can no longer be included in PEA-PME accounts but are still eligible for the traditional PEA scheme.

Ipsen announces it is no longer eligible for the PEA-PME scheme
Ipsen (Euronext: IPN; ADR: IPSEY) announces that the Group is no longer eligible for the PEA-PME scheme (a French equity savings vehicle for small and mid-sized business enterprises) as of January 1st, 2018, in accordance with Articles L221-32-2 and D221-113-5 of the French Monetary and Financial Code.
As of January 1st, 2018, the Group will no longer comply with the thresholds set by the legislator for eligibility to the PEA-PME scheme, determined on the basis of two fiscal years preceding the acquisition date of the securities i.e. the consolidated financial statements for 2016, in accordance with the French regulations.
Consequently, Ipsen Group’s securities can no longer be included in PEA-PME accounts but are still eligible for the traditional PEA scheme.

Related stories
Excellence in action: Ipsen is first pharma company to receive two Gold Shingo Prizes
Ipsen announces U.S. FDA Priority Review for palovarotene New Drug Application in patients with fibrodysplasia ossificans progressiva following resubmission
Ipsen announces the launch of an Employee Shareholding Plan
Related Press Releases
New late-breaking data reinforces IQIRVO®’s impact on ALP, fatigue and...
Ipsen announces late-breaking data from first head-to-head study comparing Dysport®...
Ipsen presents first-in-class late-breaking Phase II corabotase data in glabellar...
Ipsen unveils corabotase, a first-in-class recombinant neuroinhibitor, RNI™, at the...
Ipsen delivers strong sales in the first quarter of 2026...
Ojemda® approved in the European Union as the first targeted...
Ipsen announces that Beech Tree has obtained an exemption from...
Ipsen showcases transformative potential of early immuno-oncology pipeline at AACR
Ipsen appoints Michelle C. Werner as EVP, President of North...
Ipsen voluntarily withdraws Tazverik® (tazemetostat) in follicular lymphoma and epithelioid...